Who was studied?
Planned enrollment: up to 60 patients with advanced refractory solid tumors.
What does the publication report?
Prospective, open-label, single-arm, multicenter design; the publication describes planned methods rather than completed efficacy results.
Safety findings
Safety and toxicity are planned assessments; observed event rates are not reported here.
How should we interpret it?
This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study) · DOI: 10.1136/bmjopen-2023-075642 · PMID: 38458816
Related publications from the same research program
- PRaG 5.0: Personalized thymosin alpha-1 and radioimmunotherapy for advanced refractory solid tumors—Data from an expanded cohort.
- Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors.
- A precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumors: An open-label, prospective, multicenter clinical study (PRaG 5.0 study).
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.